AGENCIES: Sanofi SA and GlaxoSmithKline Plc toh indian authorities khan para manishe etu bi late-stage clinical trial tai khan laga protein-based COVID-19 vaccine candidate nimete.etu khobor toh drugmaker para Thursday din te koikena janaidiya thakishe.
France’s Sanofi and Britain’s GSK may te shuru kurishe global trials toh etu bi komti hoilebi 35,000 adults khan nimete etu shot toh test kuribole nimete.tai khan bhabona kuri ase etu approval; toh 2021 khotom nohoa akhe te pabole nimete eut bi joldi stage results khan dikhaishe etu vaccine para ekta robust immune response de koikena .
Etu Indian arm studies nimete komti hoilebi 3000 adults khan 18 sal aro 55 umar majhotte ase.Indian clinical trial registry hisaab te thakishe.
Etu assessment toh bhabona kuri ase ek sal nimete chulibole nimete aro akhe wala enrollment toh india te dikhaishe Tuesday din te bona toh.
Etu Indian drug regulator toh etu request nimete jawab dianai kotha kuribole nimete. Etu virus ytoh jai thaka samay ami khan bhabona kuri ase ki lagabole nimete aha moina aro sal te aro etu hisaab te ami khan vaccine development programmes khan olaishe etu khobor toh Annapurna Das, Sanofi’s India head, para statement te koikena janaishe.
India toh Thursday din te komti hoilebi 46,000 new COVID-19 cases last 24 hours te olaishe etu bi health ministry data hisaab te thakishe.experts khan dhamki dishe etu figures toh bishi wala thakibo .
Etu coronavirus laga highly contagious Delta variant etu eki technology chulai ase etu toh akhe te south asian desh te jai ase aro etu para global recovery plans khan ase aro death count toh four million duniya te paar kurishe.
GSK and Sanofi’s vaccine candidate etu eki technology chulai ase etu toh eki Sanofi’s seasonal influenza vaccines thakikena .etu toh adjuvant thakikena ekta substance kuntu toh booster nishena ase etu shot nimeter GSK para bona toh.
Sanofi toh aro bi bhabona kuri nase etu participant khan ke vaccination pabole nimete ekta approved COVID-19 shot logote etu study samay tai khan kuribole mun thakile toh.
